Growth Hackers Strengthens Market Position Through Strategic Lovable Partnership for Advanced SEO Solutions

Photo from GrowthHackers.se STOCKHOLM, Sweden, Aug. 19, 2025 (GLOBE NEWSWIRE) — Growth Hackers Sthlm AB has announced a strategic partnership with Lovable, Europe's fastest-growing AI startup, marking a significant milestone in the agency's mission to re-establish itself as the leading growth partner for AI-focused companies across Europe. The collaboration positions Growth Hackers to deliver advanced […]

Growth Hackers Strengthens Market Position Through Strategic Lovable Partnership for Advanced SEO Solutions

Growth Hackers Strengthens Market Position Through Strategic Lovable Partnership for Advanced SEO Solutions Summary: Stockholm-Based Agency Leverages AI-Powered Growth Engine to Accelerate European Startup Expansion GlobeNewswire August 20, 2025 Photo from GrowthHackers.se STOCKHOLM, Sweden, Aug. 19, 2025 (GLOBE NEWSWIRE) — Growth Hackers Sthlm AB has announced a strategic partnership with Lovable, Europe's fastest-growing AI startup,

C3.AI INVESTIGATION ALERT: Investigation Launched into C3.ai, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving C3.ai, Inc. (NYSE: AI) focused on whether C3.ai and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. https://mma.prnewswire.com/media/2542335/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg If you have information that could assist in the C3.ai investigation

XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies

XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. https://mma.prnewswire.com/media/2374018/XtalPi_EN_Logo.jpg This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments.

Bossjob’s Twin Engine Strategy Revolutionizes Talent Acquisition at Tokyo WebX Summit

Bossjob, Asia's premier Web3 talent ecosystem, has confirmed its role as a GOLD partner at the Tokyo WebX Summit on August 25-26. As the only provider offering a comprehensive talent solution that combines an AI-driven recruitment platform with top-tier headhunting, it will debut its “dual-engine drive” strategy to the Asian market at this prestigious event.

Bossjob’s Twin Engine Strategy Revolutionizes Talent Acquisition at Tokyo WebX Summit

Bossjob, Asia's premier Web3 talent ecosystem, has confirmed its role as a GOLD partner at the Tokyo WebX Summit on August 25-26. As the only provider offering a comprehensive talent solution that combines an AI-driven recruitment platform with top-tier headhunting, it will debut its “dual-engine drive” strategy to the Asian market at this prestigious event.

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS(R) and TAGRISSO(R) Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

(NASDAQ:HCM),(LSE – AIM:HCM),(HKSE:0013), HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS(R) (savolitinib) and TAGRISSO(R) (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS(R) and TAGRISSO(R) Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS(R) and TAGRISSO(R) Combination as a First-Line Therapy for Certain Lung Cancer Patients in China GlobeNewswire August 20, 2025 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Capricor Therapeutics, Inc. (CAPR)

NEW YORK, NY / ACCESS Newswire / August 19, 2025 / If you suffered a loss on your Capricor Therapeutics, Inc. (NASDAQ:CAPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/capricor-therapeutics-inc-lawsuit-submission-form-2?prid=162409&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Scroll to Top